1.
Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. Textbook of Diabetes [Internet]. 5th ed. Somerset: John Wiley & Sons, Incorporated; 2016. Available from: http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
2.
Holt RIG. Textbook of diabetes [Internet]. 4th ed. Chichester: Wiley-Blackwell; 2010. Available from: http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
3.
Crasto, W. Handbook of Insulin Therapies [Internet]. Adis; 1st ed. 2016 edition; 2016. Available from: https://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4676975
4.
Efficacy and Safety of Glucagon-like peptide-1 receptor agonists in type 2 diabetes Systematic review and mixed-treatment comparison analysis. Available from: http://onlinelibrary.wiley.com.ezproxy3.lib.le.ac.uk/doi/10.1111/dom.12849/epdf
5.
Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. Textbook of Diabetes [Internet]. 5th ed. Somerset: John Wiley & Sons, Incorporated; 2016. Available from: http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056
6.
Holt RIG. Textbook of diabetes [Internet]. 4th ed. Chichester: Wiley-Blackwell; 2010. Available from: http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077
7.
Evans M, Schumm-Draeger PM, Vora J, King AB. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes, Obesity and Metabolism. 2011 Aug;13(8):677–84.
8.
Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes, Obesity and Metabolism. 2016 Mar;18(3):203–16.
9.
Ismail-Beigi F. Glycemic Management of Type 2 Diabetes Mellitus. New England Journal of Medicine. 2012 Apr 5;366(14):1319–27.
10.
Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006 Aug 1;29(8):1963–72.
11.
Srinivasan BT, Davies M. Glycaemic management of type 2 diabetes. Medicine. 2014 Dec;42(12):711–7.
12.
Srinivasan BT, Jarvis J, Khunti K, Davies MJ. Recent advances in the management of type 2 diabetes mellitus: a review. Postgraduate Medical Journal. 2008 Oct 1;84(996):524–31.
13.
Home PD. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes, Obesity and Metabolism. 2012 Sep;14(9):780–8.
14.
June James. Safety and insulin: implementation of national guidance at a local level. Journal of Diabetes Nursing [Internet]. Available from: http://go.galegroup.com.ezproxy4.lib.le.ac.uk/ps/retrieve.do?tabID=T002&resultListType=RESULT_LIST&searchResultsType=SingleTab&searchType=AdvancedSearchForm&currentPosition=8&docId=GALE%7CA342482979&docType=Article&sort=RELEVANCE&contentSegment=&prodId=EAIM&contentSet=GALE%7CA342482979&searchId=R6&userGroupName=leicester&inPS=true
15.
Rorsman P, Renstr�m E. Insulin granule dynamics in pancreatic beta cells. Diabetologia. 2003 Aug 1;46(8):1029–45.
16.
L. Luzi. Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. American Journal of Physiology - Endocrinology and Metabolism [Internet]. 1989 Aug 1;257(2):E241–6. Available from: http://ajpendo.physiology.org.ezproxy4.lib.le.ac.uk/content/257/2/E241
17.
Luc JC van Loon. Plasma insulin responses after ingestion of different amino acid or protein mixtures with carbohydrate. The American Journal of Clinical Nutrition [Internet]. 2000 Jan 7;72(1):96–105. Available from: http://ajcn.nutrition.org/content/72/1/96.full
18.
Menting JG, Whittaker J, Margetts MB, Whittaker LJ, Kong GKW, Smith BJ, et al. How insulin engages its primary binding site on the insulin receptor. Nature. 2013 Jan 9;493(7431):241–5.
19.
Wahren J, Kallas A. Loss of Pulsatile Insulin Secretion: A Factor in the Pathogenesis of Type 2 Diabetes? Diabetes. 2012 Sep 1;61(9):2228–9.
20.
Professor Kamlesh Khunti - Coding, Classification and Diagnosis of Diabetes [Internet]. 4AD. Available from: https://www.youtube.com/watch?v=AhhWTmEFuag
21.
Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes. Diabetes Care. 2006 Jun 1;29(6):1269–74.
22.
Richter B, Neises G. ‘Human’ insulin versus animal insulin in people with diabetes mellitus. In: Cochrane Database of Systematic Reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 1996. Available from: http://doi.wiley.com/10.1002/14651858.CD003816.pub2
23.
Holman RR, Turner RC. A Practical Guide to Basal and Prandial Insulin Therapy. Diabetic Medicine. 1985 Jan;2(1):45–53.
24.
Crasto, W. Handbook of Insulin Therapies [Internet]. Adis; 1st ed. 2016 edition; 2016. Available from: https://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4676975
25.
Crasto W, Jarvis J, Hackett E, Nayyar V, McNally PG, Davies MJ, et al. Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus. Postgraduate Medical Journal. 2009 Apr 1;85(1002):219–22.
26.
Swinnen SG, Simon AC, Holleman F, Hoekstra JB, DeVries JH. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. In: Cochrane Database of Systematic Reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 1996. Available from: http://doi.wiley.com/10.1002/14651858.CD006383.pub2
27.
Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. The Lancet. 2008 Mar;371(9618):1073–84.
28.
Davies MJ, Donnelly R, Barnett AH, Jones S, Nicolay C, Kilcoyne A. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes, Obesity and Metabolism. 2009 Dec;11(12):1153–62.
29.
Garber AJ, Ligthelm R, Christiansen JS, Liebl A. Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes, Obesity and Metabolism. 2007 Sep;9(5):630–9.
30.
Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, et al. Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. New England Journal of Medicine. 2007 Oct 25;357(17):1716–30.
31.
Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. In: Cochrane Database of Systematic Reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 1996. Available from: http://doi.wiley.com/10.1002/14651858.CD005613.pub3
32.
Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study [Internet]. Available from: http://link.springer.com.ezproxy4.lib.le.ac.uk/article/10.1007/s00125-005-0132-0/fulltext.html
33.
Riddle MC, Aronson R, Home P, Marre M, Niemoeller E, Miossec P, et al. Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care. 2013 Sep 1;36(9):2489–96.
34.
Gough SCL, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM. Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naive Patients With Type 2 Diabetes: A 26-week, randomized, controlled, multinational, treat-to-target trial: The BEGIN LOW VOLUME trial. Diabetes Care. 2013 Sep 1;36(9):2536–42.
35.
Hirsch IB, Buse JB, Leahy J, McGill JB, Peters A, Rodbard HW, et al. Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. Diabetes, Obesity and Metabolism. 2014 Mar;16(3):206–14.
36.
Zinman B, Fulcher G, Rao PV, Thomas N, Endahl LA, Johansen T, et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. The Lancet. 2011 Mar;377(9769):924–31.
37.
Young LA, Buse JB. GLP-1 receptor agonists and basal insulin in type 2 diabetes. The Lancet. 2014 Dec;384(9961):2180–1.
38.
Rosenstock J, Raccah D, Koranyi L, Maffei L, Boka G, Miossec P, et al. Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care. 2013 Oct 1;36(10):2945–51.
39.
Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. The Lancet. 2010 Jun;375(9733):2234–43.
40.
New IDegLira data show rapid and predictable glycaemic improvements in people with type 2 diabetes [Internet]. Available from: http://www.multivu.com/players/English/72762519-novo-nordisk-IDegLira-treatment/
41.
Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. In: Cochrane Database of Systematic Reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 1996. Available from: http://doi.wiley.com/10.1002/14651858.CD005613.pub3
42.
Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AYM, et al. Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes. Annals of Internal Medicine. 2011 Jan 18;154(2).
43.
Rosenstock J, Jelaska A, Frappin G, Salsali A, Kim G, Woerle HJ, et al. Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes. Diabetes Care. 2014 Jul;37(7):1815–23.
44.
Frandsen CSS, Madsbad S. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review. Diabetic Medicine. 2014 Nov;31(11):1293–300.
45.
Hirsch IB, Franek E, Mersebach H, Bardtrum L, Hermansen K. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST T1). Diabetic Medicine. 2017 Feb;34(2):167–73.
46.
Rodbard HW, Bode BW, Harris SB, Rose L, Lehmann L, Jarlov H, et al. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial. Diabetic Medicine. 2017 Feb;34(2):189–96.
47.
Davies MJ, Leiter LA, Guerci B, Grunberger G, Ampudia-Blasco FJ, Yu C, et al. Impact of baseline HbA1c, diabetes duration and BMI on clinical outcomes in the LixiLan-O trial testing iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine and lixisenatide monocomponents. Diabetes, Obesity and Metabolism. 2017 Apr;
48.
Raccah D, Huet D, Dib A, Joseph F, Landers B, Escalada J, et al. Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. Diabetic Medicine. 2017 Jun 2;
49.
Daly H, Davies M, Barnett J, Amin S, Gray G, Leonard J, et al. Development of a self-management education module for those with type 2 diabetes on injectable therapies. Practical Diabetes. 2015 Oct;32(8):305–310a.
50.
Crasto, W. Handbook of Insulin Therapies [Internet]. Adis; 1st ed. 2016 edition; 2016. Available from: https://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4676975
51.
A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes [Internet]. Available from: http://link.springer.com.ezproxy4.lib.le.ac.uk/article/10.1007/s00125-007-0911-x/fulltext.html
52.
Hannele Yki-Jarvinen,Leena Juurinen,Michael Alvarsson,Tord Bystedt,Ian Caldwell,Melanie Davies. Initiate insulin by aggressive titration and education (Initiate): randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care [Internet]. Available from: http://go.galegroup.com.ezproxy4.lib.le.ac.uk/ps/retrieve.do?sort=DA-SORT&docType=Clinical+report&tabID=T002&prodId=EAIM&searchId=R1&resultListType=RESULT_LIST&searchType=AdvancedSearchForm&contentSegment=&currentPosition=5&searchResultsType=SingleTab&inPS=true&userGroupName=leicester&docId=GALE%7CA165017903&contentSet=GALE%7CA165017903
53.
Philip Raskin,Elsie Allen,Priscilla Hollander,Andrew Lewin,Robert A. Gabbay,Peter Hu. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care [Internet]. Available from: http://go.galegroup.com.ezproxy4.lib.le.ac.uk/ps/retrieve.do?sort=DA-SORT&docType=Article&tabID=T002&prodId=EAIM&searchId=R5&resultListType=RESULT_LIST&searchType=AdvancedSearchForm&contentSegment=&currentPosition=5&searchResultsType=SingleTab&inPS=true&userGroupName=leicester&docId=GALE%7CA128867472&contentSet=GALE%7CA128867472
54.
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. New England Journal of Medicine. 2008 Oct 9;359(15):1577–89.
55.
Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. New England Journal of Medicine. 2012 Jul 26;367(4):319–28.
56.
Goudswaard AN, Furlong NJ, Valk GD, Stolk RP, Rutten GE. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. In: Cochrane Database of Systematic Reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 1996. Available from: http://doi.wiley.com/10.1002/14651858.CD003418.pub2
57.
Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. The Lancet Diabetes & Endocrinology. 2013 Sep;1(1):28–34.
58.
Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, et al. Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes. New England Journal of Medicine. 2009 Oct 29;361(18):1736–47.
59.
Yki-Jarvinen H, Juurinen L, Alvarsson M, Bystedt T, Caldwell I, Davies M, et al. Initiate Insulin by Aggressive Titration and Education (INITIATE): A randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care. 2007 Jun 1;30(6):1364–9.
60.
Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R. Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005 Jun 1;28(6):1282–8.
61.
Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. The Lancet. 2014 Dec;384(9961):2228–34.
62.
Yki-Jarvinen H, Kotronen A. Is There Evidence to Support Use of Premixed or Prandial Insulin Regimens in Insulin-Naive or Previously Insulin-Treated Type 2 Diabetic Patients? Diabetes Care. 2013 Aug 1;36(Supplement_2):S205–11.
63.
Lasserson DS, Glasziou P, Perera R, Holman RR, Farmer AJ. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia. 2009 Oct;52(10):1990–2000.
64.
Wang C, Mamza J, Idris I. Biphasic vs basal bolus insulin regimen in Type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetic Medicine. 2015 May;32(5):585–94.
65.
Davies MJ, Chatterjee S. Trial watch: Insulin initiation for type 2 diabetes mellitus in primary care. Nature Reviews Endocrinology. 2017 Apr 7;13(6):317–8.
66.
Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation. Available from: http://www.journalslibrary.nihr.ac.uk/hta/volume-14/issue-11
67.
Crasto, W. Handbook of Insulin Therapies [Internet]. Adis; 1st ed. 2016 edition; 2016. Available from: https://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4676975
68.
Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. The Lancet. 2012 Apr;379(9825):1489–97.
69.
Davies MJ, Gross JL, Ono Y, Sasaki T, Bantwal G, Gall MA, et al. Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial. Diabetes, Obesity and Metabolism. 2014 Oct;16(10):922–30.
70.
Ashwell SG, Amiel SA, Bilous RW, Dashora U, Heller SR, Hepburn DA, et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. Diabetic Medicine. 2006 Mar;23(3):285–92.
71.
The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. New England Journal of Medicine. 1993 Sep 30;329(14):977–86.
72.
Nathan DM. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview. Diabetes Care. 2014 Jan;37(1):9–16.
73.
Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, et al. Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. New England Journal of Medicine. 2010 Jul 22;363(4):311–20.
74.
Kahler P, Grevstad B, Almdal T, Gluud C, Wetterslev J, Vaag A, et al. Targeting intensive versus conventional glycaemic control for type 1 diabetes mellitus: a systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. BMJ Open. 2014 Aug 19;4(8):e004806–e004806.
75.
Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. In: Cochrane Database of Systematic Reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 1996. Available from: http://doi.wiley.com/10.1002/14651858.CD009122.pub2
76.
Benkhadra K, Alahdab F, Tamhane S, Wang Z, Prokop LJ, Hirsch IB, et al. Real Time Continuous Glucose Monitoring in type 1 diabetes: A Systematic review and Individual Patient Data Meta-Analysis. Clinical Endocrinology. 2016 Dec;
77.
McCrimmon RJ. Old habits are hard to break: lessons from the study of hypoglycaemia. Diabetic Medicine. 2017 Feb;34(2):148–55.
78.
Heller SR, Colagiuri S, Vaaler S, Wolffenbuttel BHR, Koelendorf K, Friberg HH, et al. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes. Diabetic Medicine. 2004 Jul;21(7):769–75.
79.
Pickup JC, Reznik Y, Sutton AJ. Glycemic Control During Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Insulin Injections in Type 2 Diabetes: Individual Patient Data Meta-analysis and Meta-regression of Randomized Controlled Trials. Diabetes Care. 2017 May;40(5):715–22.
80.
Wang W, Liu H, Xiao S, Liu S, Li X, Yu P. Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Diabetes Therapy. 2017 Jun 14;
81.
Villani M, de Courten B, Zoungas S. Emergency treatment of hypoglycaemia: a guideline and evidence review. Diabetic Medicine. 2017 Sep;34(9):1205–11.
82.
Walker RA, Rodgers J, Diabetes UK. Diabetes: a practical guide to managing your health. Fully revised and updated. London: Dorling Kindersley; 2010.
83.
Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, et al. Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes. New England Journal of Medicine. 2009 Oct 29;361(18):1736–47.
84.
Hermansen K, Davies M. Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes, Obesity and Metabolism. 2007 May;9(3):209–17.
85.
Anderson JW, Kendall CWC, Jenkins DJA. Importance of Weight Management in Type 2 Diabetes: Review with Meta-analysis of Clinical Studies. Journal of the American College of Nutrition. 2003 Oct;22(5):331–9.
86.
Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes – causes, effects and coping strategies. Diabetes, Obesity and Metabolism. 2007 Nov;9(6):799–812.
87.
Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. BMJ. 2002 Oct 5;325(7367):746–746.
88.
Anderson B, Funnell M, American Diabetes Association. The art of empowerment: stories and strategies for diabetes educators. 2nd ed. Alexandria, Va: American Diabetes Association; 2005.
89.
Insulin treatment and the problem of weight gain in type 2 diabetes. - PubMed - NCBI [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17102158
90.
Tikkanen-Dolenc H, Wadén J, Forsblom C, Harjutsalo V, Thorn LM, Saraheimo M, et al. Frequent and intensive physical activity reduces risk of cardiovascular events in type 1 diabetes. Diabetologia. 2016 Dec 24;
91.
Peter Mansell. The dose adjustment for normal eating (DAFNE) education programme. Journal of Diabetes Nursing [Internet]. Available from: http://go.galegroup.com.ezproxy4.lib.le.ac.uk/ps/retrieve.do?tabID=T002&resultListType=RESULT_LIST&searchResultsType=SingleTab&searchType=AdvancedSearchForm&currentPosition=1&docId=GALE%7CA314268073&docType=Article&sort=Relevance&contentSegment=&prodId=EAIM&contentSet=GALE%7CA314268073&searchId=R1&userGroupName=leicester&inPS=true
92. :
Summary of Revisions. Diabetes Care. 2016 Jan;39(Supplement 1):S4–5.
93.
Effects of Intensive Glucose Lowering in Type 2 Diabetes. New England Journal of Medicine. 2008 Jun 12;358(24):2545–59.
94.
Garber AJ, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes, Obesity and Metabolism. 2006 Jan;8(1):58–66.
95.
Owens DR. Stepwise intensification of insulin therapy in Type 2 diabetes management-exploring the concept of the basal-plus approach in clinical practice. Diabetic Medicine. 2013 Mar;30(3):276–88.
96.
Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R. Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005 Jun 1;28(6):1282–8.
97.
Park SW, Bebakar WMW, Hernandez PG, Macura S, Hersløv ML, de la Rosa R. Insulin degludec/insulin aspart once daily in Type 2 diabetes: a comparison of simple or stepwise titration algorithms (BOOST : SIMPLE USE). Diabetic Medicine. 2017 Feb;34(2):174–9.
98.
Matthew C. Riddle,Julio Rosenstock,John Gerich. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care [Internet]. Available from: http://go.galegroup.com.ezproxy4.lib.le.ac.uk/ps/retrieve.do?tabID=T002&resultListType=RESULT_LIST&searchResultsType=SingleTab&searchType=AdvancedSearchForm&currentPosition=9&docId=GALE%7CA110470954&docType=Article&sort=Relevance&contentSegment=&prodId=EAIM&contentSet=GALE%7CA110470954&searchId=R3&userGroupName=leicester&inPS=true
99.
Fineman MS, Cirincione BB, Maggs D, Diamant M. GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes, Obesity and Metabolism. 2012 Aug;14(8):675–88.
100.
Frandsen CSS, Madsbad S. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review. Diabetic Medicine. 2014 Nov;31(11):1293–300.
101.
Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, et al. Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes. New England Journal of Medicine. 2009 Oct 29;361(18):1736–47.
102.
Rosenstock J, Jelaska A, Frappin G, Salsali A, Kim G, Woerle HJ, et al. Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes. Diabetes Care. 2014 Jul;37(7):1815–23.
103.
Bergenstal RM, Johnson M, Powers MA, Wynne A, Vlajnic A, Hollander P, et al. Adjust to Target in Type 2 Diabetes: Comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care. 2008 Jul 1;31(7):1305–10.
104.
Owens DR, Luzio SD, Sert-Langeron C, Riddle MC. Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month ‘proof-of-concept’ study. Diabetes, Obesity and Metabolism. 2011 Nov;13(11):1020–7.
105.
Hannele Yki-Järvinen. Is There Evidence to Support Use of Premixed or Prandial Insulin Regimens in Insulin-Naive or Previously Insulin-Treated Type 2 Diabetic Patients? Diabetes Care [Internet]. 2013;36(Suppl 2). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920773/
106.
Lankisch MR, Ferlinz KC, Leahy JL, Scherbaum WA. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes, Obesity and Metabolism. 2008 Sep;
107.
Lasserson DS, Glasziou P, Perera R, Holman RR, Farmer AJ. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia. 2009 Oct;52(10):1990–2000.
108.
Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Ceriello A, Esposito K. Efficacy of Insulin Analogs in Achieving the Hemoglobin A1c Target of <7% in Type 2 Diabetes: Meta-analysis of randomized controlled trials. Diabetes Care. 2011 Feb 1;34(2):510–7.
109.
Raccah D, Huet D, Dib A, Joseph F, Landers B, Escalada J, et al. Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. Diabetic Medicine. 2017 Jun 2;
110.
Raccah D, Huet D, Dib A, Joseph F, Landers B, Escalada J, et al. Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. Diabetic Medicine. 2017 Sep;34(9):1193–204.
111.
Martha M. Funnell. Overcoming barriers to the initiation of insulin therapy. Clinical Diabetes [Internet]. Available from: http://go.galegroup.com.ezproxy3.lib.le.ac.uk/ps/retrieve.do?sort=DA-SORT&docType=Article&tabID=T002&prodId=EAIM&searchId=R1&resultListType=RESULT_LIST&searchType=AdvancedSearchForm&contentSegment=&currentPosition=8&searchResultsType=SingleTab&inPS=true&userGroupName=leicester&docId=GALE%7CA159389875&contentSet=GALE%7CA159389875
112.
McBain H, Begum S, Rahman S, Mulligan K. Barriers to and enablers of insulin self-titration in adults with Type 2 diabetes: a qualitative study. Diabetic Medicine. 2017 Feb;34(2):253–61.
113.
Manju Chandran,Steven V. Edelman. Have insulin, will fly: diabetes management during air travel and time zone adjustment strategies. (Practical Pointers). Clinical Diabetes [Internet]. Available from: http://go.galegroup.com.ezproxy3.lib.le.ac.uk/ps/retrieve.do?tabID=T002&resultListType=RESULT_LIST&searchResultsType=SingleTab&searchType=AdvancedSearchForm&currentPosition=3&docId=GALE%7CA100730300&docType=Article&sort=Relevance&contentSegment=&prodId=EAIM&contentSet=GALE%7CA100730300&searchId=R2&userGroupName=leicester&inPS=true
114.
Burnett JCD. Long‐ and Short‐Haul Travel by Air: Issues for People With Diabetes on Insulin. Journal of Travel Medicine. 2006 Sep 1;13(5):255–60.
115.
Suggested insulin regimens for patients with type 1 diabetes mellitus who wish to fast during the month of Ramadan - ClinicalKey [Internet]. Available from: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0149291808002737
116.
Hui E, Bravis V, Salih S, Hassanein M, Devendra D. Comparison of Humalog Mix 50 with human insulin Mix 30 in type 2 diabetes patients during Ramadan. International Journal of Clinical Practice. 2010 Mar 10;64(8):1095–9.
117.
Ali S, Davies MJ, Brady EM, Gray LJ, Khunti K, Beshyah SA, et al. Guidelines for managing diabetes in Ramadan. Diabetic Medicine. 2016 Oct;33(10):1315–29.
118.
Bakiner O, Ertorer ME, Bozkirli E, Tutuncu NB, Demirag NG. Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan. Acta Diabetologica. 2009 Mar;46(1):63–5.
119.
Gregory T. Mucha,Stacia Merkel,William Thomas,John P. Bantle. Fasting and insulin glargine in individuals with type 1 diabetes. Diabetes Care [Internet]. Available from: http://go.galegroup.com.ezproxy4.lib.le.ac.uk/ps/retrieve.do?tabID=T002&resultListType=RESULT_LIST&searchResultsType=SingleTab&searchType=AdvancedSearchForm&currentPosition=17&docId=GALE%7CA116666633&docType=Article&sort=Relevance&contentSegment=&prodId=EAIM&contentSet=GALE%7CA116666633&searchId=R8&userGroupName=leicester&inPS=true
120.
Diabetes & Metabolism - Présentation - EM consulte [Internet]. Available from: http://www.em-consulte.com/article/80031/alertePM#N1010C
121.
Mollema ED, Snoek FJ, Heine RJ, Van Der Ploeg HM. Phobia of self-injecting and self-testing in insulin-treated diabetes patients: opportunities for screening. Diabetic Medicine. 2001 Dec 20;18(8):671–4.
122.
Jenkins K. II. Needle phobia: a psychological perspective. British Journal of Anaesthesia. 2014 Jul 1;113(1):4–6.
123.
Zambanini A, Newson RB, Maisey M, Feher MD. Injection related anxiety in insulin-treated diabetes. Diabetes Research and Clinical Practice. 1999 Dec;46(3):239–46.
124.
Mattoo V, Milicevic Z, Malone JK, Schwarzenhofer M, Ekangaki A, Levitt LK, et al. A comparison of insulin lispro Mix25TM and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan. Diabetes Research and Clinical Practice. 2003 Feb;59(2):137–43.
125.
Akram J, De Verga V, Group the RS. Insulin lispro (Lys(B28), Pro(B29)) in the treatment of diabetes during the fasting month of Ramadan. Diabetic Medicine. 1999 Oct;16(10):867–74.
126.
Hui E, Bravis V, Salih S, Hassanein M, Devendra D. Comparison of Humalog Mix 50 with human insulin Mix 30 in type 2 diabetes patients during Ramadan. International Journal of Clinical Practice. 2010 Mar 10;64(8):1095–9.
127.
Simmons JH, McFann KK, Brown AC, Rewers A, Follansbee D, Temple-Trujillo RE, et al. Reliability of the Diabetes Fear of Injecting and Self-Testing Questionnaire in Pediatric Patients With Type 1 Diabetes. Diabetes Care. 2007 Apr 1;30(4):987–8.
128.
Crasto, W. Handbook of Insulin Therapies [Internet]. Adis; 1st ed. 2016 edition; 2016. Available from: https://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4676975
129.
Lambert K, Holt RIG. The use of insulin analogues in pregnancy. Diabetes, Obesity and Metabolism. 2013 Oct;15(10):888–900.
130.
Hyperglycemia and Adverse Pregnancy Outcomes. New England Journal of Medicine. 2008 May 8;358(19):1991–2002.
131.
Gurwitz JH. Glucocorticoids and the Risk for Initiation of Hypoglycemic Therapy. Archives of Internal Medicine. 1994 Jan 10;154(1).
132.
Randomized controlled trial of insulin detemir versus NPH for the treatment of pregnant women with diabetes - ClinicalKey [Internet]. Available from: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0002937815005931
133.
Simmons LR, Molyneaux L, Yue DK, Chua EL. Steroid-Induced Diabetes: Is It Just Unmasking of Type 2 Diabetes? ISRN Endocrinology. 2012;2012:1–5.
134.
Riddle MC, Rosenstock J, Vlajnic A, Gao L. Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections. Diabetes, Obesity and Metabolism. 2014 May;16(5):396–402.
135.
June James. End-of-life care: Anything but a pathway. Available from: http://www.diabetesandprimarycare.co.uk/media/content/_master/3572/files/pdf/dpc15-6-292-7.pdf
136.
Frisch A, Chandra P, Smiley D, Peng L, Rizzo M, Gatcliffe C, et al. Prevalence and Clinical Outcome of Hyperglycemia in the Perioperative Period in Noncardiac Surgery. Diabetes Care. 2010 Aug 1;33(8):1783–8.
137.
Home P, Riddle M, Cefalu WT, Bailey CJ, Bretzel RG, del Prato S, et al. Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? Diabetes Care. 2014 Jun;37(6):1499–508.
138.
Jackson MJ, Patvardhan C, Wallace F, Martin A, Yusuff H, Briggs G, et al. Perioperative management of diabetes in elective patients: a region-wide audit. British Journal of Anaesthesia. 2016 Apr;116(4):501–6.
139.
Rowles S, Kilvert A, Sinclair A. ABCD position statement on diabetes and end of life care. Practical Diabetes International. 2011 Jan;28(1):26–7.
140.
P. Schneiter. Kinetics of dexamethasone-induced alterations of glucose metabolism in healthy humans. American Journal of Physiology - Endocrinology and Metabolism [Internet]. 1998 Nov 1;275(5):E806–13. Available from: http://ajpendo.physiology.org/content/275/5/E806
141.
Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy, Asthma & Clinical Immunology. 2013;9(1).
142.
Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, et al. Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. New England Journal of Medicine. 2007 Oct 25;357(17):1716–30.
143.
Kutz A, Struja T, Hausfater P, Amin D, Amin A, Haubitz S, et al. The association of admission hyperglycaemia and adverse clinical outcome in medical emergencies: the multinational, prospective, observational TRIAGE study. Diabetic Medicine. 2017 Feb;
144.
Rowles S, Kilvert A, Sinclair A. ABCD position statement on diabetes and end of life care. Practical Diabetes International. 2011 Jan;28(1):26–7.
145.
Tapley M, Needham E. Improving end of life care for people with diabetes. Practical Diabetes. 2012 Oct;29(8):306–307a.
146.
Intensity of peri-operative glycemic control and postoperative outcomes in patients with diabetes: a meta-analysis - ClinicalKey [Internet]. Available from: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0168822713001873
147.
F Game. Annals of The Royal College of Surgeons of England. 2012;94(5). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3954366/?report=classic
148.
Hommel I, van Gurp PJ, Tack CJ, Liefers J, Mulder J, Wollersheim H, et al. Perioperative diabetes care: room for improving the person centredness. Diabetic Medicine. 2015 Apr;32(4):561–8.
149.
Aldam P, Levy N, Hall GM. Perioperative management of diabetic patients: new controversies. British Journal of Anaesthesia. 2014 Dec;113(6):906–9.
150.
Barker P, Creasey PE, Dhatariya K, Levy N, Lipp A, Nathanson MH, et al. Peri-operative management of the surgical patient with diabetes 2015. Anaesthesia. 2015 Dec;70(12):1427–40.
151.
Levy N, Penfold N, Mythen M. Perioperative management of diabetes and the emerging role of anaesthetists as perioperative physicians. British Journal of Anaesthesia. 2016 Apr;116(4):443–7.
152.
Bajwa S, Baruah M, Kalra S, Kapoor M. Interdisciplinary position statement on management of hyperglycemia in peri-operative and intensive care. Journal of Anaesthesiology Clinical Pharmacology. 2015;31(2).
153.
Hwang JL, Weiss RE. Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. Diabetes/Metabolism Research and Reviews. 2014 Feb;30(2):96–102.
154.
Gururaj Setty S, Crasto W, Jarvis J, Khunti K, Davies MJ. New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. Postgraduate Medical Journal. 2016 Mar;92(1085):152–64.
155.
Crasto, W. Handbook of Insulin Therapies [Internet]. Adis; 1st ed. 2016 edition; 2016. Available from: https://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4676975
156.
Bergenstal RM, Rosenstock J, Arakaki RF, Prince MJ, Qu Y, Sinha VP, et al. A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin-Treated Patients With Type 2 Diabetes. Diabetes Care. 2012 Nov 1;35(11):2140–7.
157.
Rosenstock J, Bergenstal RM, Blevins TC, Morrow LA, Prince MJ, Qu Y, et al. Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study. Diabetes Care. 2013 Mar 1;36(3):522–8.
158.
Riddle MC, Bolli GB, Ziemen M, Muehlen-Bartmer I, Bizet F, Home PD. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1). Diabetes Care. 2014 Oct;37(10):2755–62.
159.
Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojeski M, Espinasse M, et al. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). Diabetes Care. 2015 Dec;38(12):2217–25.
160.
New Insulin Glargine 300 U/mL: Glycemic Control and Hypoglycemia in a Meta-Analysis of Phase 3a EDITION Clinical Trials in People with T2DM - ClinicalKey [Internet]. Available from: https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1499267114003086
161.
Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes - ClinicalKey [Internet]. Available from: https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858714701743
162.
Buse JB, Vilsbøll T, Thurman J, Blevins TC, Langbakke IH, Bøttcher SG, et al. Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira). Diabetes Care. 2014 Nov;37(11):2926–33.
163.
EASD Virtual Meeting [Internet]. Available from: http://www.easdvirtualmeeting.org/resources/systematic-review-and-meta-analysis-of-the-efficacy-and-safety-of-sglt2-inhibitors-in-patients-with-type-2-diabetes-mellitus
164.
Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial - ClinicalKey [Internet]. Available from: https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S0140673610606320
165.
Shosuke Satake,Mary Courtney Moore,Kayano Igawa,Margaret Converse,Benjamin Farmer,Doss W. Neal. Direct and indirect effects of insulin on glucose uptake and storage by the liver. (Original Articles). Diabetes [Internet]. Available from: http://go.galegroup.com.ezproxy4.lib.le.ac.uk/ps/retrieve.do?tabID=T002&resultListType=RESULT_LIST&searchResultsType=SingleTab&searchType=AdvancedSearchForm&currentPosition=2&docId=GALE%7CA87347789&docType=Article&sort=Relevance&contentSegment=&prodId=EAIM&contentSet=GALE%7CA87347789&searchId=R8&userGroupName=leicester&inPS=true
166.
Khedkar A, Iyer H, Anand A, Verma M, Krishnamurthy S, Savale S, et al. A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects. Diabetes, Obesity and Metabolism. 2010 Feb 27;12(8):659–64.
167.
Luzio SD, Dunseath G, Lockett A, Broke-Smith TP, New RR, Owens DR. The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes. Diabetes, Obesity and Metabolism. 2010 Jan;12(1):82–7.
168.
W. Blair Geho. A Single-blind, Placebo-controlled, Dose-ranging Trial of Oral Hepatic-directed Vesicle Insulin Add-on to Oral Antidiabetic Treatment in Patients With Type 2 Diabetes Mellitus. Journal of Diabetes Science and Technology [Internet]. 2014;8(3). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455427/
169.
Morçöl T, Nagappan P, Nerenbaum L, Mitchell A, Bell SJD. Calcium phosphate-PEG-insulin-casein (CAPIC) particles as oral delivery systems for insulin. International Journal of Pharmaceutics. 2004 Jun;277(1–2):91–7.
170.
Pozzilli P, Manfrini S, Costanza F, Coppolino G, Cavallo MG, Fioriti E, et al. Biokinetics of buccal spray insulin in patients with type 1 diabetes. Metabolism. 2005 Jul;54(7):930–4.
171.
Guevara-Aguirre J, Guevara M, Saavedra J, Mihic M, Modi P. Beneficial Effects of Addition of Oral Spray Insulin (Oralin) on Insulin Secretion and Metabolic Control in Subjects with Type 2 Diabetes Mellitus Suboptimally Controlled on Oral Hypoglycemic Agents. Diabetes Technology & Therapeutics. 2004 Feb;6(1):1–8.
172.
Kuhlmann M, Marre M. Lessons learned from biosimilar epoetins and insulins. The British Journal of Diabetes & Vascular Disease. 2010 Mar 1;10(2):90–7.
173.
Raccah D, Huet D, Dib A, Joseph F, Landers B, Escalada J, et al. Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. Diabetic Medicine. 2017 Sep;34(9):1193–204.
174.
Lea, Mary R. Creme, Phyllis. Writing At University [Internet]. 3rd ed. McGraw-Hill Education; 2008. Available from: http://ebookcentral.proquest.com.ezproxy3.lib.le.ac.uk/lib/leicester/detail.action?docID=345134
175.
Bailey S. Academic writing: a handbook for international students [Internet]. 3rd ed. London: Routledge; 2011. Available from: http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=310467
